- Home
- RXRX vs RXST Comparison
RXRX vs RXST Comparison
Compare RXRX & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXRX | RXST |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 417.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RXRX | RXST |
|---|---|---|
| Price | $4.72 | $12.72 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 11 |
| Target Price | $7.25 | ★ $11.30 |
| AVG Volume (30 Days) | ★ 24.7M | 875.0K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $43,689,000.00 | ★ $142,085,000.00 |
| Revenue This Year | $7.79 | N/A |
| Revenue Next Year | $27.32 | $4.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.75 |
| 52 Week Low | $3.79 | $6.32 |
| 52 Week High | $12.36 | $44.22 |
Technical Indicators
Market Signals| Indicator | RXRX | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 50.73 | 75.78 |
| Support Level | $4.32 | $11.20 |
| Resistance Level | $4.94 | $10.12 |
| Average True Range (ATR) | 0.28 | 0.70 |
| MACD | 0.10 | 0.23 |
| Stochastic Oscillator | 80.97 | 89.45 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.